AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully
Target
Upside 273%
Price (€) 2.05
Market Cap (€M) 84.6
Perf. 1W: -13.9%
Perf. 1M: -12.8%
Perf. 3M: 10.7%
Perf Ytd: -58.3%
10 day relative perf. to stoxx600: -20.5%
20 day relative perf. to stoxx600: -9.39%
Latest17/05/2018 10:41

Business update

Fact

Crossject has published a short release to comment on its activities.


Analysis

As we expected, the group confirmed the planning of market approval filings in Europe and the US (FY19 for Zeneo® Sumatriptan, Zeneo® Midazolam, Zeneo® Adrenaline, Zeneo® Hydrocortisone, Zeneo® Naloxone, FY20 for Zeneo® Methotrexate and Zeneo® Terbutaline). It also confirmed ongoing negotiations for a licensing agreement concerning Zeneo® Sumatriptan in the US with a possible outcome by mid-2018. The production line for gas generators has been approved from a regulatory standpoint, a necessary step to see the production lines approved and the production ramp-up for the bioequivalence studies. All in all, this is good news, in particular since the group does not mention any delays compared to what was previously communicated to the market, a reassuring point since this has not always been the case in the past. For those who have been patient, the reward is getting nearer by the day.


Impact

We will not change our numbers and opinion on the release. We will, however, update our model shortly, particularly to take into account the new NTE (Zeneo® Terbutaline) Crossject intends to market. Half-year results are due on 26 September.


Updates

05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

22 Mar 18 Earnings/sales releases
On its way to reach the market…

03 Feb 18 Other news/comments
Orphan disease status for Zeneo® Midazolam i...

11 Dec 17 Other news/comments
Update on the company’s activities

25 Sep 17 Earnings/sales releases
H1 17: a new NTE in the pipeline...and further d...

06 Apr 17 Financing issue
The capital increase was successful

.